| Drug General Information |
| Drug ID |
D0C9EN
|
| Former ID |
DIB011134
|
| Drug Name |
AZD5312
|
| Indication |
Prostate cancer [ICD9: 185; ICD10:C61]
|
Phase 1 |
[1]
|
|---|
| Company |
Astrazeneca; isis pharmaceuticals
|
| Target and Pathway |
| Target(s) |
Androgen receptor |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
Oocyte meiosis
|
|
Pathways in cancer
|
|
Prostate cancer
|
|
NetPath Pathway
|
EGFR1 Signaling Pathway
|
|
AndrogenReceptor Signaling Pathway
|
|
FSH Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Coregulation of Androgen receptor activity
|
|
Regulation of Androgen receptor activity
|
|
Nongenotropic Androgen signaling
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
FOXA1 transcription factor network
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
Nuclear Receptor transcription pathway
|
|
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02144051) Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors. U.S. National Institutes of Health. |
|---|
